Forte Biosciences Inc
FBRX11.435USD
+1.135+11.02%
Fechamento 11/06, 16:00（ET）Cotações atrasadas em 15 min
140.44MValor de mercado
PerdaP/L TTM
Mais detalhes de Forte Biosciences Inc Empresa
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Informações de Forte Biosciences Inc
Código da empresaFBRX
Nome da EmpresaForte Biosciences Inc
Data de listagemApr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
Número de funcionários14
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 13
Endereço3060 Pegasus Park Drive
CidadeDALLAS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal75247
Telefone13106186994
Sitehttps://www.fortebiorx.com/home/default.aspx
Código da empresaFBRX
Data de listagemApr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
Executivos da empresa Forte Biosciences Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
82.09K
+1.42%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.70K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
82.09K
+1.42%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.70K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 4 de nov
Atualizado em: ter, 4 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Federated Hermes Global Investment Management Corp.
13.15%
Fred Alger Management, LLC
13.02%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
Outro
46.65%
Investidores
Investidores
Proporção
Federated Hermes Global Investment Management Corp.
13.15%
Fred Alger Management, LLC
13.02%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
Outro
46.65%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
45.54%
Hedge Fund
25.35%
Private Equity
10.18%
Investment Advisor
7.24%
Corporation
3.95%
Individual Investor
1.03%
Research Firm
0.08%
Outro
6.64%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
77
10.98M
88.35%
+3.99M
2025Q2
80
7.19M
109.15%
+1.76M
2025Q1
80
5.91M
89.79%
+471.51K
2024Q4
82
5.78M
90.44%
+3.18M
2024Q3
72
948.15K
58.94%
-63.60K
2024Q2
79
972.89K
60.86%
-40.06K
2024Q1
108
982.74K
67.53%
-37.22K
2023Q4
121
973.92K
67.03%
-54.29K
2023Q3
139
1.01M
71.78%
+97.73K
2023Q2
175
455.32K
54.14%
-352.22K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Federated Hermes Global Investment Management Corp.
1.48M
11.89%
+406.41K
+37.90%
Aug 31, 2025
Fred Alger Management, LLC
1.62M
13.02%
+708.04K
+77.75%
Jun 30, 2025
Janus Henderson Investors
1.39M
11.22%
+474.85K
+51.61%
Jun 30, 2025
OrbiMed Advisors, LLC
1.20M
9.63%
+603.87K
+101.82%
Jun 30, 2025
Tybourne Capital Management (HK) Limited
786.65K
6.33%
+166.67K
+26.88%
Jun 30, 2025
BVF Partners L.P.
588.34K
4.73%
-5.94K
-1.00%
Jun 30, 2025
Cable Car Capital LLC
500.00K
4.02%
+280.40K
+127.68%
Jun 30, 2025
Sphera Funds Management Ltd.
495.11K
3.98%
+495.11K
--
Jun 30, 2025
The Vanguard Group, Inc.
486.92K
3.92%
+397.97K
+447.40%
Jun 30, 2025
Ikarian Capital LLC
476.44K
3.83%
-132.78K
-21.80%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: há 20 horas
Atualizado em: há 20 horas
Nome
Proporção
Alger 35 ETF
3.45%
Texas Capital Texas Small Cap Equity Index ETF
0.07%
iShares Micro-Cap ETF
0.02%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Alger Mid Cap 40 ETF
0%
Avantis US Small Cap Equity ETF
0%
Alger 35 ETF
Proporção3.45%
Texas Capital Texas Small Cap Equity Index ETF
Proporção0.07%
iShares Micro-Cap ETF
Proporção0.02%
Dimensional US Core Equity 1 ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
Alger Mid Cap 40 ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Data
Tipo
Proporção
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
